ClinicalTrials.gg
RecruitingNCT05370833Updated Jul 12, 2023

Transcranial Direct Current Stimulation in Clinical Setting to Reduce Pain in Older Workers

An interventional study of transcranial direct current stimulation in Chronic Pain and Aging, sponsored by Université de Sherbrooke. Recruiting at 2 sites in Canada. Open to participants aged 56 Years and older. Per ClinicalTrials.gov, last updated 2023-07-12.

Sponsored by Université de Sherbrooke · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
56 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Chronic Pain by Université de Sherbrooke — 8 open to participants now, 9 under way, none of them phase 3. Chronic Pain · Université de Sherbrooke.

Planned enrollment
8th of 11
24 · median 32
Started
2022
with 3 others
No phase
10 of 15
7 open now
Registered
11th of 15
by date

Among the 15 studies in Chronic Pain by Université de Sherbrooke, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2022, is one of 10 with no phase, and was the 11th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

8 of the 15 studies in Chronic Pain by Université de Sherbrooke are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 56 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Chronic Pain by Université de Sherbrooke, or all of them as a file.
02

Study summary

Chronic pain is one of the main factors influencing workers' retention at work. Considering that the prevalence of suffering from chronic pain increases with age, older workers are most likely to be absent from work because of their pain.

Transcranial direct current stimulation (tDCS) is a treatment option to reduce chronic pain.

This study aims to document the effect of tDCS on pain and work retention in older workers and to compare the traditional tDCS protocol (5 sessions) with an enhanced protocol (11 sessions).

Read the detailed description

Chronic pain affects many spheres of the lives of affected individuals and those around them. In Canada, the prevalence of chronic pain is estimated at 15% of adults aged 18 and over. Among seniors, the prevalence of this health problem can reach up to 50% and affect one in two seniors. Chronic pain is one of the leading causes of work disability. In this context, pain reduction remains one of the most effective methods to enable the worker to stay at work. Considering the aging Quebec population, labor needs and the average retirement age which is increasingly postponed, it becomes crucial to take an interest in aging workers and their continued employment.

Transcranial direct current stimulation (tDCS) is a non-invasive neurostimulation method that has shown promise in reducing chronic pain. Recently, several research teams have shown that tDCS has beneficial effects on pain, physical function and social participation in seniors. Despite all these recent advances, very few studies have focused on optimizing tDCS treatment modalities and no studies have focused on the impact of tDCS on return to work or retention. The vast majority of studies using tDCS to reduce pain give one tDCS session per day for 5 consecutive days. This study aims to document the effect of tDCS on pain and work retention in older workers and to compare the traditional tDCS protocol (5 sessions) with an enhanced protocol (11 sessions).

03

Conditions studied

  • Chronic Pain
  • Aging

Browse trials for

Keywords

  • transcranial direct current stimulation
  • physical therapy
  • work retention
04

Who can participate

Ages eligible
56 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • To be more than 55 years old
  • To have chronic pain
  • To have employment relationship
  • To have pain that interferes with work tasks

Exclusion criteria

Exclusion Criteria:

  • tDCS (epilepsy, metallic implant in the head, pacemaker, cochlear implant)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Standard protocol

    5 tDCS sessions in 1 week

    Device: transcranial direct current stimulation

  • Experimental
    Enhanced protocol

    11 tDCS sessions devised in 4 weeks

    Device: transcranial direct current stimulation

Interventions

  • Devicetranscranial direct current stimulation

    Anodal, 2mA, tDCS session applied on M1 for 20 minutes.

06

What researchers measure

Primary outcomes

  1. Pain intensity

    0-10 Numerical rating scale

    Time frame: Before tDCS

  2. Pain intensity

    0-10 Numerical rating scale

    Time frame: 1 week

  3. Pain intensity

    0-10 Numerical rating scale

    Time frame: 4 weeks

  4. Pain intensity

    0-10 Numerical rating scale

    Time frame: 4 weeks after the last tDCS session

  5. Disability

    Pain Disability Index

    Time frame: Before tDCS

  6. Disability

    Pain Disability Index

    Time frame: 1 week

  7. Disability

    Pain Disability Index

    Time frame: 4 weeks

  8. Disability

    Pain Disability Index

    Time frame: 4 weeks after the last tDCS session

  9. Work role functioning

    Work Role Functioning Questionnaire

    Time frame: Before tDCS

  10. Work role functioning

    Work Role Functioning Questionnaire

    Time frame: 1 week

  11. Work role functioning

    Work Role Functioning Questionnaire

    Time frame: 4 weeks

  12. Work role functioning

    Work Role Functioning Questionnaire

    Time frame: 4 weeks after the last tDCS session

  13. Physical Functioning

    Brief Pain Inventory

    Time frame: Before tDCS

  14. Physical Functioning

    Brief Pain Inventory

    Time frame: 1 week

  15. Physical Functioning

    Brief Pain Inventory

    Time frame: 4 weeks

  16. Physical Functioning

    Brief Pain Inventory

    Time frame: 4 weeks after the last tDCS session

  17. Anxiety

    Beck anxiety inventory

    Time frame: Before tDCS

  18. Anxiety

    Beck anxiety inventory

    Time frame: 1 week

  19. Anxiety

    Beck anxiety inventory

    Time frame: 4 weeks

  20. Anxiety

    Beck anxiety inventory

    Time frame: 4 weeks after the last tDCS session

  21. Depression

    Beck depression inventory

    Time frame: Before tDCS

  22. Depression

    Beck depression inventory

    Time frame: 1 week

  23. Depression

    Beck depression inventory

    Time frame: 4 weeks

  24. Depression

    Beck depression inventory

    Time frame: 4 weeks after the last tDCS session

  25. Impression of change

    Patient Global impression of change

    Time frame: 1 week

  26. Impression of change

    Patient Global impression of change

    Time frame: 4 weeks

  27. Impression of change

    Patient Global impression of change

    Time frame: 4 weeks after the last tDCS session

  28. Central sensitization

    central sensitization inventory

    Time frame: Before tDCS

  29. Central sensitization

    central sensitization inventory

    Time frame: 1 week

  30. Central sensitization

    central sensitization inventory

    Time frame: 4 weeks

  31. Central sensitization

    central sensitization inventory

    Time frame: 4 weeks after the last tDCS session

Secondary outcomes

  1. Recruitment

    Feasibility of the study

    Time frame: through study completion, about 2 years

  2. Security

    Feasibility of the study

    Time frame: through study completion, about 2 years

  3. Intervention

    Feasibility of the study

    Time frame: through study completion, about 2 years

07

Study locations

1 of 2 sites recruiting
  • Clinique régionale de la gestion de la douleur - CISSSAT
    Rouyn-Noranda, Quebec, Canada
    Recruiting
    • Rodrigo Deamo, PhD · Contact
  • Centre de Recherche sur le Vieillissement
    Sherbrooke, Quebec J1H 4C4, Canada
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: Yes — Upon request to the corresponding author

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Upon request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Apr 2024, 23 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 23 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2022
First posted
May 12, 2022
StartActual
May 15, 2022
Primary completionEst.
Apr 30, 2024
CompletionEst.
May 30, 2024
Last update
Jul 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05370833
Collaborators
CISSS Abitibi-Témiscamingue
Responsible party
Guillaume Léonard (Professor, Université de Sherbrooke) — Principal investigator
First posted
May 12, 2022
Start date
May 15, 2022
Primary completion
Apr 30, 2024 (estimated)
Completion
May 30, 2024 (estimated)
Last update
Jul 12, 2023

Study contacts

Guillaume Leonard, PhD
Contact
guillaume.leonard2@usherbrooke.ca
819-780-2220 ext. 45246
Guillaume Leonard, PhD
principal investigator · Université de Sherbrooke

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion